CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.02B, above the global median of $1.15B
- PositionReturn on equity is -189.5%, lower than 95% of its Biotechnology peers (median -24.5%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.02BUSDvs all stocks (USD)
Revenue (TTM)
217.17MUSDvs all stocks (USD)
Profit Margin
-112.01%vs Biotechnology peers
Beta
0.3690xvs all stocks
52-Week Change
134.33%vs all stocks
Market Capitalization
2.02BUSDvs all stocks (USD)
Enterprise Value
2.00BUSDvs all stocks (USD)
Forward P/E
-44.76xvs Biotechnology peers
Price to Sales (TTM)
9.30xvs Biotechnology peers
Price to Book (MRQ)
48.51xvs Biotechnology peers
Enterprise to Revenue
9.23xvs Biotechnology peers
Enterprise to EBITDA
-8.96xvs Biotechnology peers
Gross Margin
95.94%vs Biotechnology peers
Profit Margin
-112.01%vs Biotechnology peers
Operating Margin
-52.73%vs Biotechnology peers
Return on Assets (TTM)
-25.12%vs Biotechnology peers
Return on Equity (TTM)
-189.53%vs Biotechnology peers
Revenue (TTM)
217.17MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.49USDUpdated Jul 19, 2026Quarterly Revenue Growth
223.60%vs Biotechnology peers
Gross Profit (TTM)
-50.33MUSDvs all stocks (USD)
EBITDA (TTM)
-223.77MUSDvs all stocks (USD)
Net Income (TTM)
-243.25MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
223.64%vs Biotechnology peers
Operating Cash Flow (TTM)
-278.16MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-186.01MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
172.35MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.97MUSDFY2025 · Dec 31, 2025Gross Profit
165.38MUSDFY2025 · Dec 31, 2025Operating Income
-273.08MUSDvs all stocks (USD)
Pre-tax Income
-285.42MUSDFY2025 · Dec 31, 2025Net Income
-285.42MUSDFY2025 · Dec 31, 2025EBIT
-251.64MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-251.63MUSDFY2025 · Dec 31, 2025Research & Development
258.78MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
179.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
22.73MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
33.78MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.29USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.29USDFY2025 · Dec 31, 2025Basic Shares Outstanding
86.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
86.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-285.42MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-343.52MUSDFY2025 · Dec 31, 2025Free Cash Flow
-343.71MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
135.03MUSDFY2025 · Dec 31, 2025Interest Paid
13.19MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-285.42MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
47.50MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.34MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-79.81MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.95MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-32.09MUSDFY2025 · Dec 31, 2025Capital Expenditures
-187.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-195.81MUSDFY2025 · Dec 31, 2025Sale of Investments
486.03MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
290.04MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
88.54MSharesUpdated Jul 19, 2026Float Shares
79.61MSharesUpdated Jul 19, 2026Shares Short
21.81MSharesUpdated Jul 19, 2026Short Ratio
9.13daysvs all stocks
Short % of Shares Outstanding
25.05%vs all stocks
% Held by Insiders
1.70%vs all stocks
% Held by Institutions
117.25%vs all stocks
Total Cash (MRQ)
361.24MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.08USDUpdated Jul 19, 2026Total Debt (MRQ)
345.36MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
8.30xvs Biotechnology peers
Current Ratio (MRQ)
5.47xvs Biotechnology peers
Book Value per Share (MRQ)
0.4700USDUpdated Jul 19, 2026Total Assets
529.71MUSDvs all stocks (USD)
Total Current Assets
528.08MUSDFY2025 · Dec 31, 2025Total Liabilities
465.08MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.63MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
344.96MUSDFY2025 · Dec 31, 2025Total Current Liabilities
120.12MUSDFY2025 · Dec 31, 2025Cash Equivalents
134.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
134.93MUSDFY2025 · Dec 31, 2025Other Short-term Investments
278.76MUSDFY2025 · Dec 31, 2025Accounts Receivable
38.00MUSDFY2025 · Dec 31, 2025Inventory
32.75MUSDFY2025 · Dec 31, 2025Accounts Payable
16.58MUSDFY2025 · Dec 31, 2025Short-term Debt
472.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
10.53MUSDFY2025 · Dec 31, 2025Long-term Debt
344.96MUSDFY2025 · Dec 31, 2025Common Stock (Book)
9.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.51BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
64.63MUSDvs all stocks (USD)
52-Week Low
9.38USDUpdated Jul 19, 202652-Week High
25.59USDUpdated Jul 19, 202652-Week Change
134.33%vs all stocks
Beta
0.3690xvs all stocks
50-Day MA
20.38USDUpdated Jul 19, 2026200-Day MA
20.12USDUpdated Jul 19, 2026Avg 10-Day Volume
1.99MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.34MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.79USDUpdated Jul 19, 2026Other Income / Expense
-1.28MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -189.5%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -1.90Industry median: -0.25Industry P5: -1.55Peers compared: 197
Debt-to-equity is 8.3×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 8.30Industry median: 0.10Industry P95: 2.96Peers compared: 197
Price-to-book is 48.51×, higher than 95% of its Biotechnology peers (median 5.36×)Significant
Price-to-book: 48.51Industry median: 5.36Industry P95: 37.43Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.96Profit Margin: -1.12
Significant cash reserves alongside high leverageNotable
Cash (USD): 361,239,008Total Debt (USD): 345,360,000Debt-to-Equity: 8.30
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.47Altman Z-Score: -1.69
Financial Health
Altman Z-Score -1.69: distress zoneCritical
Altman Z-Score: -1.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.02B, above the global median of $1.15BNotable
Market cap (USD): 2,020,308,615Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Nuvation Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rapport Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC